Virologic failure and immune suppression over study visits.

a<p>Number of virologic failures is indicated by x, number of available VL measurements are indicated by n.</p>b<p>Number of CD4 counts defining suppressed immune function indicated by x, number of available CD4 counts indicated by n.</p

Effect of depressive symptoms on nonadherence and clinical outcomes.

a<p>Adjusted for baseline measurement of age, gender, marital status, education, and household assets.</p>b<p>Any self-reported deviation from perfect ART adherence was used as indicator for nonadherence.</p>c<p>Failure/suppression at any point after baseline measurement, adjusted for baseline measure of failure/suppression.</p

Associations between risk factors and lack of ART initiation among HIV-seropositive patients with CD4 at or below 350 cells/mm³ enrolled in CNICS (including deaths) with inverse probability of censoring weighting, 2003–2012.

<p>Associations between risk factors and lack of ART initiation among HIV-seropositive patients with CD4 at or below 350 cells/mm³ enrolled in CNICS (including deaths) with inverse probability of censoring weighting, 2003–2012.</p

Characteristics of HIV-seropositive Patients Enrolled in CNICS, 2003–2012.

<p>Characteristics of HIV-seropositive Patients Enrolled in CNICS, 2003–2012.</p

Association between clinical characteristics and lack of ART initiation across two enrollment periods among HIV-seropositive patients enrolled in CNICS (including deaths) with inverse probability of censoring weighting, 2003–2012.

<p>Association between clinical characteristics and lack of ART initiation across two enrollment periods among HIV-seropositive patients enrolled in CNICS (including deaths) with inverse probability of censoring weighting, 2003–2012.</p

Demographics and clinical characteristics at study entry one year after ART initiation and over 25,581 person-years of follow-up among 7183 patients who initiated antiretroviral therapy between January 1, 1998 and December 31, 2009 and survived for at least one year at 8 US clinical sites, followed for death up to 5 years.

<p>ARV, antiretroviral; IQR, interquartile range; MSM, men who have sex with men; ART, antiretroviral therapy; AIDS, acquired immunodeficiency syndrome; VL, viral load.</p>a<p>Unavailable.</p>b<p><500 copies/ML.</p

Estimated effect of HAART on mortality among 790 HIV-infected children initiating HIV care in Kinshasa, DRC, between December 2004 and May 2010.

<p>All estimates are derived from pooled logistic models that include time modeled as a restricted cubic spline with four knots. Comparing HAART to no HAART, the unadjusted mortality rate ratio was 0.54 (95% CI 0.34–0.85), while the unadjusted ratio of 3-y mortality risks was 0.31 (95% CI 0.23–0.43).</p

Cumulative mortality for patients in care and lost to clinic.

<p>Crude (grey) and standardized (black) survival curves compare mortality between patients continuously retained in care at CNICS sites (solid lines) and patients lost to clinic (dotted lines) among 7183 patients who initiated antiretroviral therapy between January 1, 1998 and December 31, 2009 and survived for at least one year at 8 US clinical sites, followed for death up for 5 years.</p

Cumulative incidence curves depicting the effect of HAART on survival among 790 HIV-infected children.

<p>In (A), the curves are unweighted. In (B), the curves are weighted by the IPTCV.</p

Five-year risk ratios and risk differences comparing mortality between patients continuously retained in care at CNICS sites and patients lost to clinic among 7183 patients who initiated antiretroviral therapy between January 1, 1998 and December 31, 2009 and survived for at least one year at 8 US clinical sites, followed for death up to 5 years.

<p>CI, Confidence interval; RR, risk ratio; RD, risk difference.</p>a<p>Cumulative mortality risk was calculated as the complement of the Kaplan-Meier survival curve at 5 and 10 years.</p>b<p>Confidence intervals based on 200 nonparametric bootstrap resamples.</p>c<p>For sex, age, race, ethnicity, AIDS status at baseline, antiretroviral-therapy-naive at baseline, sexual orientation, injection drug use at baseline, CD4 cell count, viral load at baseline, and calendar date of ART initiation, and time-varying CD4 cell count, viral load, and AIDS status.</p